Bayer Entered into a Collaboration Agreement with Bicycle Therapeutics for the Development of Novel Targeted Radionuclide Therapies in Oncology
Shots:
- Bicycle will receive $45M up front, ~$223.8M in development & regulatory/first commercial sale milestones, or ~$672.18M across all 3 target programs along with royalties. Bayer will be responsible for the fund & other activities
- Bicycle will also receive high single-digit millions upon 3rd target selection (which Bayer has a one-time right to expand the collaboration to include 3rd target program), high single-digit millions as a one-time option fee, or low single-digit millions in the quarterly payments bringing the total deal value to ~$1.7B
- The collaboration will strengthen Bayer’s oncology development pipeline with the addition of targeted radiotherapeutics using Bicycle’s peptide-based technology
Ref: Bayer | Image: Bayer
Related News:- Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
